Talk to people attending the event, share your expectations
Over the past year, immunotherapies as monotherapies and combination regimes have gained approval from FDA and EMA for targeting various types of tumors. The FDA Modernization Act 2.0 has also brought excitement to the field, inspiring experts to improve success rates in the clinic. At the Annual Tumour Models London Summit, you can gain practical insights through case studies to enhance your candidate selection workflows. Join us to meet pioneers in oncology and accelerate your product's journey from lab to patient with optimized translatability, efficiency, and cost-effectiveness. AstraZeneca, Ichnos Science, Breakpoint Therapeutics, and more will share their model selection criteria based on cancer type to help you streamline your selection process.
Popular among visitors for
Top 100 in Science & Research in United Kingdom